Insilico Medicine, a China-based biotech company driven by generative artificial intelligence (AI), has entered into a partnership with Hutao Tech, a Beijing-based life science data specialist. The collaboration aims to combine Hutao’s market resources and industry expertise in life science data with Insilico’s AI drug development platform, Pharma AI, and its intelligent robotics laboratory, Life Star1, to enhance the intelligent development of precision medicine and conduct translational research.
The partnership will focus on the joint development of automated precision medicine and drug screening laboratory solutions. Hutao will contribute its insights into clinical research and translational medicine, drawing on its experience in medical institutions. This includes imaging data governance platforms, research-level clinical data governance platforms, research hospital development, and the transformation of collaborative research achievements. Insilico, on the other hand, will design and provide a multi-module platform solution tailored to various scenario requirements. This will encompass PandaOmics for multi-group information analysis, Chemistry42 for drug screening, and integrated services for precision medicine laboratory construction and operation.- Flcube.com
